Citations (28)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (5)
Muhammad Umair Mushtaq, Alexandra M. Harrington, Sibgha Gull Chaudhary, Laura C. Michaelis, Karen-Sue B. Carlson, Sameem Abedin, Lyndsey Runass, Natalie S. Callander, Michael J. Fallon, Mark Juckett, Aric C. Hall, Peiman Hematti, Ryan J. Mattison, Ehab L. Atallah & Guru Subramanian Guru Murthy. (2021) Comparison of salvage chemotherapy regimens and prognostic significance of minimal residual disease in relapsed/refractory acute myeloid leukemia. Leukemia & Lymphoma 62:1, pages 158-166.
Read now
Read now
Matteo Molica, Massimo Breccia, Saveria Capria, Silvia Trisolini, Roberto Foa, Elias Jabbour & Tapan Mahendra Kadia. (2020) The role of cladribine in acute myeloid leukemia: an old drug up to new tricks. Leukemia & Lymphoma 61:3, pages 536-545.
Read now
Read now
Bolun Wang, Hui Lyu, Shanshan Pei, Deye Song, Jiangdong Ni & Bolin Liu. (2018) Cladribine in combination with entinostat synergistically elicits anti-proliferative/anti-survival effects on multiple myeloma cells. Cell Cycle 17:8, pages 985-996.
Read now
Read now
Chantal Fridle, Michael Medinger, Matthias C. Wilk, Katja Seipel, Jakob Passweg, Markus G. Manz & Thomas Pabst. (2017) Cladribine, cytarabine and idarubicin (CLA-Ida) salvage chemotherapy in relapsed acute myeloid leukemia (AML). Leukemia & Lymphoma 58:5, pages 1068-1075.
Read now
Read now
Silvia Castegnaro, Carlo Visco, Katia Chieregato, Martina Bernardi, Elena Albiero, Cristina Zanon, Domenico Madeo & Francesco Rodeghiero. (2012) Cytosine arabinoside potentiates the apoptotic effect of bendamustine on several B- and T-cell leukemia/lymphoma cells and cell lines. Leukemia & Lymphoma 53:11, pages 2262-2268.
Read now
Read now
Articles from other publishers (23)
Susu Cao, Qianshan TaoJia WangQing ZhangYi Dong. (2023) Cladribine, cytarabine, and filgrastim based regimen in relapsed or refractory acute myeloid leukemia: A systematic review and meta-analysis. Medicine 102:44, pages e34949.
Crossref
Crossref
Xinhong Fei, Weijie Zhang, Jiangying Gu, Fan Yang, Tingting Li, Wenjing Wang & Jingbo Wang. (2023) CLAG combined with total body irradiation as intensive conditioning chemotherapy prior to allogeneic hematopoietic stem cell transplantation in patients with refractory or relapsed acute myeloid leukemia. Annals of Hematology.
Crossref
Crossref
Sean G Rudd, Nikolaos Tsesmetzis, Kumar Sanjiv, Cynthia BJ Paulin, Lakshmi Sandhow, Juliane Kutzner, Ida Hed Myrberg, Sarah S Bunten, Hanna Axelsson, Si Min Zhang, Azita Rasti, Petri Mäkelä, Si'Ana A Coggins, Sijia Tao, Sharda Suman, Rui M Branca, Georgios Mermelekas, Elisée Wiita, Sun Lee, Julian Walfridsson, Raymond F Schinazi, Baek Kim, Janne Lehtiö, Georgios Z Rassidakis, Katja Pokrovskaja Tamm, Ulrika Warpman‐Berglund, Mats Heyman, Dan Grandér, Sören Lehmann, Thomas Lundbäck, Hong Qian, Jan‐Inge Henter, Torsten Schaller, Thomas Helleday & Nikolas Herold. (2020)
Ribonucleotide reductase inhibitors suppress
SAMHD
1 ara‐
CTP
ase activity enhancing cytarabine efficacy
. EMBO Molecular Medicine 12:3.
Crossref
Crossref
Peipei Ye, Renzhi Pei, Jie Jin, Jie Sun, Kongfei Li, Junjie Cao, Dandan Zhou & Ying Lu. (2019) Modified cladribine, cytarabine, and G-CSF as a salvage regimen in patients with relapsed/refractory acute myeloid leukemia: a bridge to myeloablative allogeneic hematopoietic stem cell transplantation. Annals of Hematology 98:9, pages 2073-2080.
Crossref
Crossref
Li Wang, Jun Xu, Xiaolong Tian, Tingting Lv & Guolin Yuan. (2019) Analysis of Efficacy and Prognostic Factors of CLAG Treatment in Chinese Patients with Refractory or Relapsed Acute Myeloid Leukemia. Acta Haematologica 141:1, pages 43-53.
Crossref
Crossref
Jingbo Wang, Jie Zhao, Xinhong Fei, Yuming Yin, Haoyu Cheng, Weijie Zhang, Jiangying Gu, Fan Yang, Yixin Yang, Song Xue, Zhengqin Tian, Junbao He, Shuqin Zhang & Xiaocan Wang. (2018) A new intensive conditioning regimen for allogeneic hematopoietic stem cell transplantation in patients with refractory or relapsed acute myeloid leukemia. Medicine 97:17, pages e0228.
Crossref
Crossref
Shoko Goto, Hiroaki Goto & Tomoko Yokosuka. (2016) The combination effects of bendamustine with antimetabolites against childhood acute lymphoblastic leukemia cells. International Journal of Hematology 103:5, pages 572-583.
Crossref
Crossref
Nestor Ramos, Clifton Mo, Judith Karp & Christopher Hourigan. (2015) Current Approaches in the Treatment of Relapsed and Refractory Acute Myeloid Leukemia. Journal of Clinical Medicine 4:4, pages 665-695.
Crossref
Crossref
Craig W. Freyer, Neha Gupta, Meir Wetzler & Eunice S. Wang. (2015) Revisiting the role of cladribine in acute myeloid leukemia: An improvement on past accomplishments or more old news?. American Journal of Hematology 90:1, pages 62-72.
Crossref
Crossref
Michael V. Jaglal, Vu H. Duong, Celeste M. Bello, Najla H. Al Ali, Eric Padron, Hugo F. Fernandez, Alan F. List, Jeffrey E. Lancet & Rami S. Komrokji. (2014) Cladribine, cytarabine, filgrastim, and mitoxantrone (CLAG-M) compared to standard induction in acute myeloid leukemia from myelodysplastic syndrome after azanucleoside failure. Leukemia Research 38:4, pages 443-446.
Crossref
Crossref
Nobuya Hiraoka, Jiro Kikuchi, Takahiro Yamauchi, Daisuke Koyama, Taeko Wada, Mitsuyo Uesawa, Miyuki Akutsu, Shigehisa Mori, Yuichi Nakamura, Takanori Ueda, Yasuhiko Kano & Yusuke Furukawa. (2014) Purine Analog-Like Properties of Bendamustine Underlie Rapid Activation of DNA Damage Response and Synergistic Effects with Pyrimidine Analogues in Lymphoid Malignancies. PLoS ONE 9:3, pages e90675.
Crossref
Crossref
Vikramjeet Singh, Elke Verena Voss, Karelle Bénardais & Martin Stangel. (2012) Effects of 2-Chlorodeoxyadenosine (Cladribine) on Primary Rat Microglia. Journal of Neuroimmune Pharmacology 7:4, pages 939-950.
Crossref
Crossref
Carlo Visco, Silvia Castegnaro, Katia Chieregato, Martina Bernardi, Elena Albiero, Cristina Zanon, Domenico Madeo & Francesco Rodeghiero. (2012) The cytotoxic effects of bendamustine in combination with cytarabine in mantle cell lymphoma cell lines. Blood Cells, Molecules, and Diseases 48:1, pages 68-75.
Crossref
Crossref
Lia Gore & Margaret Macy. 2011. Principles of Anticancer Drug Development. Principles of Anticancer Drug Development
589
601
.
Mike G. Martin, John S. Welch, Kristan Augustin, Lindsay Hladnik, John F. DiPersio & Camille N. Abboud. (2009) Cladribine in the Treatment of Acute Myeloid Leukemia: A Single-Institution Experience. Clinical Lymphoma and Myeloma 9:4, pages 298-301.
Crossref
Crossref
Krysta D. Schlis & Scott A. Armstrong. 2009. Oncology of Infancy and Childhood. Oncology of Infancy and Childhood
403
416
.
Alison R. Walker, Rami S. Komrokji, Jainulabdeen Ifthikharuddin, Patti Messina, Deborah Mulford, Michael Becker, Jonathan Friedberg, Jamie Oliva, Gordon Phillips, Jane L. Liesveld & Camille Abboud. (2008) Phase I study of cladribine, cytarabine (Ara-C), granulocyte colony stimulating factor (G-CSF) (CLAG Regimen) and simultaneous escalating doses of imatinib mesylate (Gleevec) in relapsed/refractory AML. Leukemia Research 32:12, pages 1830-1836.
Crossref
Crossref
Agnieszka Wierzbowska, Tadeusz Robak, Agnieszka Pluta, Ewa Wawrzyniak, Barbara Cebula, Jerzy Hołowiecki, Sławomira Kyrcz-Krzemień, Sebastian Grosicki, Sebastian Giebel, Aleksander B. Skotnicki, Beata Piątkowska-Jakubas, Kazimierz Kuliczkowski, Marek Kiełbiński, Krystyna Zawilska, Janusz Kłoczko & Agata Wrzesień-Kuś. (2007) Cladribine combined with high doses of arabinoside cytosine, mitoxantrone, and G-CSF (CLAG-M) is a highly effective salvage regimen in patients with refractory and relapsed acute myeloid leukemia of the poor risk: a final report of the Polish Adult Leukem. European Journal of Haematology 80:2, pages 115-126.
Crossref
Crossref
Roberto Scatena, Patrizia Bottoni, Giorgia Botta, Giuseppe E. Martorana & Bruno Giardina. (2007) The role of mitochondria in pharmacotoxicology: a reevaluation of an old, newly emerging topic. American Journal of Physiology-Cell Physiology 293:1, pages C12-C21.
Crossref
Crossref
Ronald W. Stam, Monique L. Boer & Rob Pieters. (2006) Towards targeted therapy for infant acute lymphoblastic leukaemia. British Journal of Haematology 132:5, pages 539-551.
Crossref
Crossref
Tieran Han, Marilyn Fernandez, Ting-Chao Chou & Ram P. Agarwal. (2005) Quantitation of synergism of arabinosylcytosine and cladribine against the growth of arabinosylcytosine-resistant human lymphoid cells. Journal of Cancer Research and Clinical Oncology 131:9, pages 609-616.
Crossref
Crossref
Ryungsa Kim. (2005) Unknotting the roles of Bcl-2 and Bcl-xL in cell death. Biochemical and Biophysical Research Communications 333:2, pages 336-343.
Crossref
Crossref
Gunnar Juliusson, Martin Höglund, Karin Karlsson, Christina Löfgren, Lars Möllgård, Christer Paul, Ulf Tidefelt & Magnus Björkholm. (2003) Increased remissions from one course for intermediate-dose cytosine arabinoside and idarubicin in elderly acute myeloid leukaemia when combined with cladribine. A randomized population-based phase II study. British Journal of Haematology 123:5, pages 810-818.
Crossref
Crossref